3 FTSE stocks in focus: Cohort PLC, Seeing Machines and PureTech Health PLC

Summary

  • Many international investors are now overweight on London markets
  • Cohort Plc’s wholly-owned subsidiary, ELAC SONAR GmbH, received an order worth £41.96 million from Leonardo S.p.A
  • PureTech Health Plc has signed a clinical trial agreement with BeiGene Ltd.

UK markets are once again on the radar of many global investors, with FTSE 100 index hovering around its year high, though there have been some recent corrections, but the mood is positive, and many international investors are overweight on London markets.

On domestic development, housing has been a runaway success story supported by the government initiatives, however, the house prices in the UK saw a dip of 0.5% in June month with the average housing price coming down at £260,358 compared to £261,642 in May month, a fall for the first time since January 2021 after the end of the stamp duty holiday, which seeks zero purchase tax on properties worth up to £500,000. During the stamp duty holiday, the average housing prices in the UK showed an upward trend, and property prices were up by 8.8% then a year ago. Other sectors have though started moving with many deals and acquisition development happening recently.

Copyright © 2021 Kalkine Media

Let us focus on 3 FTSE listed companies that have been making news:

Cohort Plc (LON: CHRT)

Cohort Plc operates in the defence and security market. It provides several products which have application in defence warships and submarines. Additionally, the company offers training and simulation, research and technical support services. It has operations in the United Kingdom, South American and other European countries.  

The company’s wholly-owned subsidiary, ELAC SONAR GmbH, received an order worth £41.96 million from Leonardo S.p.A, a leader in the design and supply of naval defence systems. As part of the contract, the company will provide sonar systems for submarines, including technical services and training tools.

The work on the contract will start immediately and expected to complete in the year 2030, with options to provide a sonar system for additional two submarines.

Cohort Plc shares were trading at GBX 591.98, down by 0.17% on 8 July at 8.15 am GMT+1 with a market cap of £243.38 million. In the last one year, the stock has given 7.5% returns to its shareholders.

PureTech Health Plc (LON: PRTC)

The company operates in the biopharma sector with the main focus on clinical-stage biotherapeutics. The company develops and markets medicine for diseases like inflammatory, fibrotic intractable cancers gastrointestinal diseases. The company’s products have FDA clearance and European marketing authorization.

The company has recently announced an agreement of clinical trial and supply with BeiGene Ltd, a Nasdaq listed biopharma company. Both companies will be doing research and development in antibody for the possible treatment of difficult-to-treat solid tumor.

PureTech Plc stocks were trading at GBX 336.1, down by 1.29% on 8 July at 8.43 am GMT+1 with a market cap of £975.64 million. In the last one year, the stock has given 27% returns to its shareholders.

Seeing Machine Ltd (LON: SEE)

Seeing Machine provides AI-powered driver monitoring technologies to improve the overall safety levels in the transport sector. The company works as an OEM (original equipment manufacturer) that sells and licenses its products and services. The company caters to, aviation, rail markets, automotive and off-road vehicles segments.

The company has signed an agreement with Airservices Australia to provide the company’s Artificial Intelligence technology. The program’s cost is valued at A$250K, which includes integrating high-level signals to keep track of workload, fatigue and attention to support a safe and effective air traffic control environment.

Seeing Machine stocks were trading at GBX 9.90, down by 0.8% on 8 July at 8.30 am GMT+1 with a market cap of £376.7 million. In the last one year, the stock has given 200% returns to its shareholders.

Comment


Disclaimer